A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-20

Study Completion Date

2020-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open, pilot study using the oral ORMD-0801 insulin formulation in patients with NASH and confirmed type 2 DM or pre-diabetes. The study will consist of a Screening, placebo run-in, treatment phase and end-of-study phase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients

NCT04483947

Non-alcoholic Steatohepatitis (NASH)

COMPLETED PHASE1

Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis

NCT05680233

Nonalcoholic Steatohepatitis Nonalcoholic Fatty Liver

COMPLETED PHASE1

Recombinant Leptin Therapy for Treatment of Nonalcoholic Steatohepatitis (NASH)

NCT00596934

Fatty Liver Disease, Nonalcoholic

COMPLETED PHASE2

Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH

NCT00267670

Nonalcoholic Steatohepatitis Liver Diseases

COMPLETED PHASE2/PHASE3

Treating Nonalcoholic Steatohepatitis (NASH) With Metformin

NCT00063232

Hepatitis

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This exploratory study will first enroll 10 patients with NASH and type 2 DM, to evaluate the safety of oral insulin and to measure the change in liver fat content.

At the completion of their 4-week follow-up period, results will be presented to the Helsinki Committee. Following approval, an additional 20 patients will be enrolled. The size of the study population was determined by the investigator (with literature review) to be sufficient to show trends of reducing liver fat content by analysis of MRI PDFF (MRI-Proton Density Fat Fraction) images, the FibroMax™ Test and Fibroscan® including Controlled Attenuation Parameter (CAP™). CAP™ is a measure of the ultrasound attenuation to quantify steatosis in the liver.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Alcoholic Steatohepatitis (NASH) Type2 Diabetes Mellitus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Oral Insulin

treatment

Group Type EXPERIMENTAL

Oral Insulin

Intervention Type BIOLOGICAL

all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oral Insulin

all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Known type 2 DM according to American Diabetic Association (one of the three needed): Fasting Plasma Glucose ≥126 mg/dl or 2h postprandial (PG) following 75g OGTT ≥ 200 mg/dl or HbA1C \> 5.7% or on treatment with metformin
* Abdominal ultrasound (US) proven fatty liver performed within 6 months before randomization, confirmed by central US.
* Fat concentration in the liver of S2 (moderate steatosis, 6-32% hepatocytes with steatosis) or more as measured by Fibromax.
* Signature of the written informed consent.
* Negative pregnancy test at study entry for females of child bearing potential.
* Females must have a negative urine pregnancy test result at screening, prior to the start of the run-in period, and at initiation of active dosing. A negative urine and serum pregnancy test must be obtained prior to active dosing. Males and females of childbearing potential must use two methods of contraception.
* Females of non-childbearing potential are defined as postmenopausal who a) had more than 24 months since last menstrual cycle with menopausal levels of FSH, b) who are surgically menopausal.
* For hypertensive patients, hypertension must be controlled by stable dose of anti-hypertensive medication for at least 2 months prior to screening with BP \< 150/\<95 mmHg
* Patients previously treated with vitamin E (\>400IU/day).
* Glycaemia must be controlled (Glycosylated Hemoglobin A1C ≤9%) while any HbA1C increment should not exceed 1% during 6 months prior to enrolment).

Exclusion Criteria

* Patients with active (acute or chronic) liver disease other than NASH (e.g. viral hepatitis, genetic hemochromatosis, Wilson disease, alpha 1antitripsin deficiency, alcohol liver disease, drug induced liver disease) at the time of randomization.
* ALT or AST ≥ 2 times ULN
* Abnormal synthetic liver function (serum albumin ≤3.5gm%, INR \>1.3).
* Known alcohol and/or any other drug abuse or dependence in the last five years.
* Weight \>120 Kg
* Known history or presence of clinically significant cardiovascular, gastrointestinal, metabolic (other than diabetes mellitus), neurologic, pulmonary, endocrine, psychiatric, neoplastic disorder or nephrotic syndrome.
* History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs including bile salt metabolites (e.g. inflammatory bowel disease (IBD), previous intestinal (ileal or colonic) operation, chronic pancreatitis, celiac disease or previous vagotomy.
* Weight loss of more than 5% within 6 months prior to randomization.
* History of bariatric surgery.
* Uncontrolled blood pressure BP ≥150/95.
* Non type 2 DM (type I, endocrinopathy, genetic syndromes etc).
* Patients with HIV.
* Daily alcohol intake \>20 g/day for women and \>30 g/day for men.
* Treatment anti-diabetic medications other than metformin, such as DPP-4 inhibitors, GLP-1 receptor agonists, TZDs, etc.
* Metformin, Fibrates, Statins, not provided on a stable dose in the last 6 months.
* Patients who are treated with Valproic acid, Tamoxifen, Methotrexate, Amiodaron.
* Chronic treatment with antibiotics (e.g. Rifaximin).
* Homeopathic and/or Alternative treatments.
* Uncontrolled hypothyroidism defined as Thyroid Stimulating Hormone \>2X the upper limit of normal (UNLN).
* Patients with renal dysfunction: eGFR\< 40 ml/min.
* Unexplained serum creatinine phosphokinase

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No